Compare Gartner Inc (IT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Mesoblast Limited — how do they compare? Gartner Inc trades at $191.18 (market cap $12.34B), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: Gartner Inc is far larger — about 7.1× Mesoblast Limited's market cap, and Gartner Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 64 Days and Mesoblast Limited for 15 Days on average.
| IT | MESO | |
|---|---|---|
Market Cap | $12.34B | $1.75B |
Volume | 919,809 | 239,027 |
Sector | Technology | Health |
52-Week High | $258.17 | $20.96 |
52-Week Low | $125.68 | $13.19 |
Typical Hold Time | 64 Days | 15 Days |
Enterprise Value | $14.08B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $191.15, up 2.9% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 69.63% gross margins, and 113.58% ROE. Recent news highlights AI advisory demand growth and the upcoming Gartner IT Symposium. Cash flow trends show operational strength despite negative net cash flow in 2025.
Outlook remains positive with AI-driven consulting demand supporting growth, though risks include shareholder investigation and competitive pressures. Analyst consensus at $174.63 suggests caution despite 27.78% buy ratings. The stock's high P/B ratio of 160.06 warrants monitoring for valuation sustainability.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
